¡¶µÆ²ÝÉ®ÈË2Ö®°×Éßǰ´«¡·¸ßÇåÈ«¼¯ÔÚÏßÃâ·ÑԢĿ - ÒÕÊõ..."/> ×ÜÖ®£¬ÉÏÊöÏÖʵÁîËû±¬·¢Á˺ÜÖØµÄÐÄÀí¼ç¸º¡£"/>
¡¶¡¶µÆ²ÝÉ®ÈË2Ö®°×Éßǰ´«¡·¸ßÇåÈ«¼¯ÔÚÏßÃâ·ÑԢĿ - ÒÕÊõ...¡·¾çÇé¼ò½é£º×ÜÖ®ÉÏÊöÏÖʵÁîËû±¬·¢Á˺ÜÖØµÄÐÄÀí¼ç¸ºÌì·çÕâÀÏ¼Ò»ï»¹ÕæÊÇÉáµÃ¾ÍËãÀÏ×ÓÏÖÔÚ¶¼Ã»ÓÐ·âµØËû¾¹È»Ò»ÏÂ×Ó¸øÄÇС×ÓÕâô´ó·âµØÒ²²»ÅÂÄÇС×ÓÔì·´°¡¡¶µÆ²ÝÉ®ÈË2Ö®°×Éßǰ´«¡·¸ßÇåÈ«¼¯ÔÚÏßÃâ·ÑԢĿ - ÒÕÊõ...Ìì·ç֤ȯÑб¨ÒÔΪÊÜÒæÓÚծȯÊг¡×ßÇ¿½ñÄêÀí²ÆÊг¡ÌåÏÖÖ𲽺ÃתÀí¹¤ÒµÆ·µ¥Î»ÆÆ¾»ÂÊ´Ó2022Äê12Ô·ݷåÖµµÄ29.2%Ò»Á¬Ï»¬ÖÁ2023Äê5ÔÂ12ÈÕµÄ4.7%µþ¼ÓÕâһʱÆÚÏ»¬µÄ´æ¿îÀûÂÊÀí¹¤ÒµÆ·¶ÔסÃñµÄÎüÒýÁ¦Ò»Ö±ÔöÇ¿´Ó5Ô·ÝÀí²Æ¹æÄ£ÉÏ¿´Ëæ×ÅÆÆ¾»ÂʽøÒ»²½»ØÂäסÃñ»¹ÔÚ¼ÌÐøÔöÅäÀí¹¤ÒµÆ·
¡¶¡¶µÆ²ÝÉ®ÈË2Ö®°×Éßǰ´«¡·¸ßÇåÈ«¼¯ÔÚÏßÃâ·ÑԢĿ - ÒÕÊõ...¡·ÊÓÆµËµÃ÷£ºÍò¿ÆA£ºÄâ·Ç¹ûÕæ¿¯ÐÐA¹É¹ÉƱļ×ʲ»³¬150ÒÚÔªÏà´«¹ÅʱÓÐÈËΪÁËÕòѹаËî»á½«×ï´ó¶ñ¼«Ö®È˵ÄÁé»ê·âÓÚÌÒľ֮ÖÐÔÙÔÔÓÚµØÏÂÒÔÌÒľ֮ÑôÆøÕòÖ®µ«Õâ°ì·¨¼«ËðÒõµÂÈô·ÇÍò²»µÃÒѾø²»»áÓÐÈËʹÓÃÕÅÀÏÏÈÉúÚ¹Ê͵À
Dr.Ali Bazarbachi: Basically, there are two kinds of breakthroughs in immunotherapy for Hodgkin Lymphoma. We have Brentuximab Vedotin (BV), which is an anti-CD30 antibody-drug conjugate. We also have checkpoint inhibitors, like anti-PD-1, both of which are highly effective in Hodgkin Lymphoma. And actually, they can be used at different stages of treatment of Hodgkin Lymphoma. Part of frontline therapy in combination with chemotherapy, salvage therapy for relapsed patients as a bridge to auto-consolidation after auto-transplant, salvage therapy for relapse after auto-transplant bridge to allo-transplant, and even for relapse after allo-transplant. So, they have changed the landscape of Hodgkin Lymphoma treatment.
Èà³ÉÒ»¸öƽ»¬µÄÃæÍÅ·ÅÔÚÎÂůµÄµØ·½·¢½ÍÖÁÁ½±¶´ó
2025-10-17 20:03:29